Fundz

Glucotrack

Rutherford, New Jersey, United States · Biotechnology, Healthcare

Glucotrack, Inc. is focused on the design, development, and commercialization of novel technologies for people with diabetes, including a long-term implantable continuous blood glucose monitoring system. The Glucotrack CBGM is an Investigational Device and is limited by federal (or United States) law to investigational use.

Key facts

Headquarters
Rutherford, New Jersey, United States
Employees
15
Industries
Biotechnology, Healthcare
Status
Public (GCTK)
Website
glucotrack.com
LinkedIn
Company page

Recent activity at Glucotrack

  • : SEC 8-K (1.01): On October 22, 2026, Glucotrack, Inc. entered into a securities purchase agreement with certain investors, resulting in the issuance of senior secured convertible promissory notes totaling $2,564,102.65 for a cash price of $2,000,000. The notes bear an interest rate of 8% per annum, maturing nine months after issuance, and are secured by the company's assets. The notes are convertible at specified prices, with a total cap on the issuance of shares limited to 19.99% of common stock outstanding prior to the agreement, pending stockholder approval. This financing aims to strategically enhance the company's liquidity and business operations.
  • : SEC 8-K (1.01):
  • : SEC 8-K (1.01):
  • : SEC 8-K (1.01): On September 24, 2026, Glucotrack, Inc. entered into a securities purchase agreement with certain institutional investors for a registered direct offering. This agreement involves the sale of an aggregate of 169,388 shares of the Company's common stock at a price of $2.04 per share, along with pre-funded warrants allowing the purchase of up to 1,350,220 additional shares at a similar price. The offering aims to raise funds for corporate purposes and addresses strategic financial needs. The terms reflect a calculated approach to enhance equity capital while remaining attractive to investors.
  • : GLUCOTRACK, INC. Secures Funding through Direct Stock Offering
  • : SEC 8-K (7.01): On September 23, 2026, Glucotrack, Inc. issued a shareholder update regarding company developments and future strategies. This update is intended to provide insights and information relevant to shareholders, enhancing transparency about the company's operational progress. While the specific content of the update is available in Exhibit 99.1, it is crucial for security holders interested in the latest corporate initiatives and strategic direction. The filing takes place as a Regulation FD disclosure, ensuring compliance with fair disclosure regulations.
  • : SEC 8-K (5.02): On September 14, 2026, Paul V. Goode resigned from the Board of Directors of Glucotrack, Inc. The resignation is effective immediately and is due to perceived conflict of interest regarding ongoing discussions related to the merger agreement with Lokahi Therapeutics, Inc. This change may impact the governance and strategic direction of Glucotrack, particularly as it navigates the complexities of the merger. The company provided Mr. Goode with necessary disclosures before filing this report.
  • : SEC 8-K (1.01):
  • : SEC 8-K (1.01): On September 10, 2026, Glucotrack, Inc. entered into a securities purchase agreement which involved issuing senior secured convertible promissory notes totaling $11,596,172.68. This transaction included cash consideration of $4,500,000 and the exchange of $4,545,014.69 of outstanding notes. The Notes, which have an 8% annual interest rate and mature in nine months, secure a lien on all assets of the Company. They are convertible at specific prices and subject to conditions based on the stock's performance, impacting future dilution and stockholder approval requirements for additional shares. This agreement represents a strategic financing move for Glucotrack, enhancing its capital structure amidst operational endeavors.
  • : SEC 8-K (1.01):

Glucotrack funding history

DateRoundAmount
Sep 2026Post-IPO Equity$346K
Jul 2026VentureUndisclosed
Dec 2017Seed$425K
Apr 2016Seed$1.1M

Leadership

  • Brandon Calavan, Director of Engineering
  • Revan Schwartz, Director
  • Michael Hauck, Director
  • Angela Strand, Director
  • Leslie Seff, Director
  • Robert Fischell, Director
  • Eugene Naidis, Executive Officer, Director
  • John Graham, Executive Officer, Director

Verified email and direct lines for Glucotrack’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.

Glucotrack in the news

Companies similar to Glucotrack

About Glucotrack: questions and answers

What does Glucotrack do?

Glucotrack, Inc. is focused on the design, development, and commercialization of novel technologies for people with diabetes, including a long-term implantable continuous blood glucose monitoring system. The Glucotrack CBGM is an Investigational Device and is limited by federal (or United States) law to investigational use.

Where is Glucotrack headquartered?

Glucotrack is headquartered in Rutherford, New Jersey, United States.

How many employees does Glucotrack have?

Glucotrack has about 15 employees.

Has Glucotrack raised funding?

Yes. Fundz has recorded 4 funding events for Glucotrack. The most recent, Post-IPO Equity of $346K, was in Sep 2026.

What is the latest news on Glucotrack?

On Oct 22, 2026, SEC 8-K (1.01): On October 22, 2026, Glucotrack, Inc. entered into a securities purchase agreement with certain investors, resulting in the issuance of senior secured convertible promissory notes totaling $2,564,102.65 for a cash price of $2,000,000. The notes bear an interest rate of 8% per annum,

Is Glucotrack a public company?

Yes. Glucotrack is publicly traded under the ticker GCTK.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Glucotrack across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.